key: cord-1046723-992q2ewt
authors: Mohamed, Dina Zakaria; Ghoneim, Mai El-Sayed; Abu-Risha, Sally El-Sayed; Abdelsalam, Ramy Ahmed; Farag, Mohamed Abdelhalem
title: Gastrointestinal and hepatic diseases during the COVID-19 pandemic: Manifestations, mechanism and management
date: 2021-07-28
journal: World J Gastroenterol
DOI: 10.3748/wjg.v27.i28.4504
sha: b32434ad3ceeb66efb7fc5cda8c644f169f80c1a
doc_id: 1046723
cord_uid: 992q2ewt

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is considered the causative pathogen of coronavirus disease 2019 (COVID-19) and has become an international danger to human health. Although respiratory transmission and symptoms are still the essential manifestations of COVID-19, the digestive system could be an unconventional or supplementary route for COVID-19 to be transmitted and manifested, most likely due to the presence of angiotensin-converting enzyme 2 (ACE2) in the gastrointestinal tract. In addition, SARS-CoV-2 can trigger hepatic injury via direct binding to the ACE2 receptor in cholangiocytes, antibody-dependent enhancement of infection, systemic inflammatory response syndrome, inflammatory cytokine storms, ischemia/reperfusion injury, and adverse events of treatment drugs. Gastrointestinal symptoms, including anorexia, nausea, vomiting, and diarrhea, which are unusual in patients with COVID-19, and some digestive signs may occur without other respiratory symptoms. Furthermore, SARS-CoV-2 can be found in infected patients’ stool, demonstrating the likelihood of transmission through the fecal-oral route. In addition, liver function should be monitored during COVID-19, particularly in more severe cases. This review summarizes the evidence for extra-pulmonary manifestations, mechanisms, and management of COVID-19, particularly those related to the gastrointestinal tract and liver.

SARS-CoV-2 first originated in China in December 2019 and critically threatened worldwide health [4, 5] . On February 12, 2021, 108 million cases and 2 million deaths have been recorded in over 219 countries and regions worldwide [6] . The lung is the primary organ involved in COVID-19 pneumonia, and most COVID-19 patients suffer typical respiratory symptoms (e.g., dyspnea, cough with sputum production, fatigue, and in severe cases, acute respiratory distress syndrome (ARDS), respiratory failure, and even death). On the other hand, extrapulmonary clinical manifestations of COVID-19 affect multiple other organs including cardiovascular (e.g., arrhythmias, myocarditis, pericarditis, acute coronary syndrome, and heart failure), renal (e.g., acute kidney injury and acute tubular necrosis), hepatic [e.g., elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin], gastrointestinal (e.g., diarrhea, nausea, vomiting, and abdominal pain), ocular (e.g., epiphora, conjunctivitis, and chemosis), dermatologic (e.g., erythematous rash, urticaria, and chickenpox-like vesicles), and neurological systems (e.g., headache, neuropathy, encephalopathy, cerebrovascular disorders, and dizziness)[7] (Figure 1 ). Considering all the previously mentioned data, this article examines the effects of gastrointestinal (GI) and hepatic symptoms, their associated mechanisms, and management caused by SARS-CoV-2 infection and provides a guide for clinical prevention and treatment ( Figure 2 ).

For SARS-CoV-2, the incubation period is an average of 4-5 d, with most patients having symptoms before 14 d, although there have been instances where the incubation period was longer [8] . The infection and hospitalization onset was documented from 9.1 to 12.5 d and emphasizes the difficulty in the early stage of the diagnosis and isolation of populations [9] . The average period for recovering patients from initial symptoms is 22 d, and for those who succumbed the time to death is approximately Young et al [208] , 2020 18 NA 3 (17) NA Tabata et al [209] , 2020 104 NA 8 (9.6) NA Wölfel et al [210] , [215] , 2020 267 Nausea: 6 (2.2) 10 (3.7) NA Wen et al [216] , 2020 417 NA 29 (7) NA Anorexia: 101(50.2) Nausea: 59 (29.4) Dan et al [217] , 2020 305

Vomiting: 3 (2) 146 (49.5) 12 (6) Ma et al [218] , 2020 81 NA 6(7.41) NA study conducted by Jin et al [42] , which was the first COVID-19 study outside Wuhan, reported that the incidence of GIT symptoms was 11.4%; diarrhea was the most common of these symptoms (8.14%) [42] . In New York, GIT symptoms have been identified in a single-center-case series, which included 892 cases. The most common symptom was diarrhea (19.8%), accompanied by nausea (16.6%), abdominal pain (7.8%), vomiting (10.2%), and anorexia (11.8%) [43] . An additional retrospective study conducted in New York showed that of 1059 COVID-19 patients, 22% had diarrhea, 6% had nausea, 19% had vomiting, and 7% had abdominal pain [44] . In addition to these studies, the pooled prevalence of GI symptoms was found to be 17.6 % in a meta-analysis of 60 studies involving 4243 cases in 6 countries The most frequent symptom was anorexia (26.8%), accompanied by diarrhea (12.5%), nausea/vomiting (10.2%) and stomach pain/discomfort (9.2%) [45] .

Furthermore, Goyal et al [46] indicated that hyperlipidemia was found in 11.7% of patients affected by SARS-CoV-2 where 92 patients out of 756 with COVID-19, had elevated serum lipase levels, resulting in acute pancreatitis. Therefore, COVID-19 patients with hyperlipidemia have an approximately 3-fold higher risk of poor clinical outcomes, including the need for ICU admission, mechanical ventilation, and death [46] .

The study by Gadiparthi et al [47] showed that the higher Glasgow Blatchford bleeding score was 7 and 11 in 2 of 3 patients on admission and represents a high risk of gastrointestinal bleeding (GIB) with a need for intervention of more than 50%. However, both young patients responded by carefully controlling hemodynamic parameters, levels of hematocrit or hemoglobin, transfusion of packed red blood cells as needed and medical therapy. Although GIB was resolved, two patients died due to respiratory failure [47] .

Besides GIT symptoms, autopsies of COVID-19 patients showed that there are gross and microscopic changes in the GIT. Segmental dilation and stenosis of the small intestine, accompanied by mucosal shedding and necrosis was described at autopsy, whereas colitis, inflammatory infiltrates, and interstitial edema, were found on histopathology imaging [48, 49] . Lui et al [50] have shown pneumatosis, intestinalis, pneumoperitoneum, ascites, and thickening bowel wall in addition to ileus on abdominal imaging. Therefore, abnormalities of the GIT can be obvious on imaging.

Based on these previous data, physicians must realize that the key characteristics of COVID-19 infection before respiratory symptoms may be digestive symptoms and, in rare instances may be the only COVID-19 symptoms to occur.

Direct infection of gastrointestinal cells: The entry of SARS-CoV-2 virus into host cells is the main part of cross-species transmission. All coronaviruses bind to receptors and mediate their entry via glycoprotein and spike proteins [51] . It has been recognized that ACE2 mainly contains receptors for SARS-CoV[52], and dipeptidyl peptidase 4, for MERS-CoV [53] . A plethora of studies has shown that the spike (S) protein of SARS-CoV-2 has a high host ACE2 affinity [54] , and enters host cells via the ACE2 receptor [55] as shown in Figure 3 .

In small intestine cells, ACE2 is usually located and strongly expressed in type II epithelial cells [56, 57] . It is considered an important enzyme in the renin-angiotensin system (RAS) [58, 59] and plays an essential role in controlling inflammation and diarrhea [60] . Moreover, its deficiency leads to the accumulation of angiotensin II (ANG II) [61] . Subsequent studies[12,62-64] have proven that SARS-CoV-2, in COVID-19 patients, may invade the GIT via ACE2 receptors, causing digestive symptoms. It is now well acknowledged that the significant upsurge of ANG II level in COVID-19 patients is the cause of progression and severity of the disease.

Although in the mouse colon, the knockdown of ACE2 by the virus leads to an upsurge of ANG II levels; ACE2 does not primarily act via the intestinal RAS system but controls the homeostasis of intestinal amino acids, gut microbes and the expression of antimicrobial peptides [65] . Mice with blocked ACE2, for example, have significantly inhibited serum tryptophan that is important to the body's niacin synthesis[66], therefore, inadequate intake of tryptophan or niacin results in pellagra [65] . It is wellrecognized that tryptophan is absorbed on the lumen surface of intestinal epithelial cells via the B0AT1/ACE2 transport route and induces the mammalian target of rapamycin, which controls the consequently appearance of antimicrobial peptides, thereby having a direct influence on components of intestinal flora [65] . Ultimately, more than 90% of pellagra patients will develop colitis [67] . Hence, it is considered that SARS-CoV-2 attachment to the ACE2 in the GIT lowers the critical receptor level, disrupting the absorption of tryptophan and ultimately destroying the steady-state of the gut flora, resulting in diarrhea.

Furthermore, He et al [68] demonstrated that the pathological results of autopsies on COVID-19 patients indicated that proinflammatory cytokines (PICs) such as tumor growth factor-β1, monocyte chemokine-1 (MCP-1), tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6 were highly expressed in ACE2-expressing cells. There is an absence of PICs in cells that do not express ACE2. Numerous PICs produce the cytokine storm, which finally leads to multiple organ failure. Besides, plasma IL-2, recombinant human interferon (IFN)-induced protein-10, MCP-1, macrophage inflammatory protein-1A, IL-7, granulocyte colony-stimulating factor, IL-10, and TNF-α levels in COVID-19 patients were higher than those in healthy people [25] . Dendritic cells and macrophages show low levels of IFN and high levels of PICs and chemokines in the early stage of SARS-CoV infection [69] [70] [71] . Later, there is a rise in cytokine and chemokine levels, which causes severe tissue damage due to the large number of inflammatory cells, such as neutrophils and monocytes. In the same manner, SARS-CoV-2 can induce cells expressing ACE2 to release inflammatory cytokines, leading to the cytokine storm and multiple organ failure [72] . Furthermore, cytokine storms can have an effect on immune cells; lymphocytosis is known to be a common sign in severe cases of COVID-19, with a significant decline in the number of B, CD8+ and CD4+T cells as well as natural killer cells, which leads to lymph node necrosis, spleen atrophy, hepatomegaly, renal hemorrhage, necrosis, and degeneration of neurons [73] .

Thromboembolic complications are being increasingly documented in COVID-19 [74]. Acute mesenteric ischemia (AMI) has been reported in severe COVID-19 patients in addition to deep venous thrombosis and pulmonary embolism [75] . It has been demonstrated that ANG II stimulates the expression of tissue factor VIII (FVIII), von Willebrand factor, and plasminogen activator inhibitor-1 by endothelial cells, resulting in a state of hypercoagulation [76, 77] . Histology of the small intestine secondary to mesenteric thrombosis revealed a prominent endothelium of the submucosa with evidence of direct viral invasion of endothelial cells along with diffuse endothelial swelling with mononuclear cell infiltrate. It is understood that there is stimulation of alternate and lectin complement trajectories [C5b-9 (membrane attack complex), C4d, and mannose-binding protein-associated serine protease 2] that destroy endothelial cells [78] . SARS-CoV-2 infection also resulted in an elevation of ANG II levels and other prothrombotic proteins, which led to AMI[78-81].

Gastrointestinal damage caused by lung infection: Any change in intestinal flora constituents affects the respiratory tract, via the common mucous immune system. Reciprocally, any damage to the respiratory tract mainly affects the digestive tract via immune regulation. This effect is known as the "gut-lung axis" [82, 83] . Furthermore, SARS-CoV-2 cannot be detected in the stools of COVID-19 patients with digestive symptoms and thus GIT symptoms may not be affected by the direct damage caused (1) Gut-lung axis: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds with angiotensin-converting enzyme 2 (ACE2) to enter the lung, which leads to the accumulation of angiotensin II (ANG II) and the reduction of Angiotensin (1-7). ANG II combined with angiotensin 1 receptor stimulates cytokine release and causes an upsurge of C-C chemokine receptor type 9 (CCR9) CD4T cells. Chemokine (C-C motif) ligand 25 subsequently enhances the recruitment of CCR9 CD4T cells into the small intestine. The changing flora then stimulates the polarization of T helper 17 cells, and eventually, interleukin 17A induces the recruitment of neutrophils. Cytokines and intestinal bacteria also enter the lung through the bloodstream, further affecting lung inflammation; and (2) Gut-liver axis: SARS-CoV-2 binds with ACE2 to enter the intestine, prevents absorption of the B0AT1/ACE2 transport pathway, and then decreases the stimulation of mammalian target of rapamycin to diminish the expression of antimicrobial peptides which result in gastrointestinal tract symptoms or enhanced ANG II that leads to the upregulation of tissue factor VIII, Von Willebrand factor, and plasminogen activator inhibitor-1 expression by endothelial cells resulting in mesenteric thrombosis. The intestinal flora, through the portal vein, is transferred to the liver, where it binds to toll-like receptors resulting in hepatitis. Additionally, the liver, can transport metabolites to the intestine via the biliary tract,. COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; ACE2: Angiotensin-converting enzyme 2: ANG II: Angiotensin II; Ang1-7: Angiotensin (1-7); AT1R: Angiotensin 1 receptor; CCR9: C-C chemokine receptor type 9; CCL25: Chemokine (C-C motif) ligand 25; Th17: T helper 17; IL-17: Interleukin 17; PMNS: July 28, 2021

Volume 27 Issue 28

Polymorphonuclear neutrophils; B0AT1: Sodium-dependent neutral amino acid transporter; mTOR: Mammalian target of rapamycin; AMPs: Antimicrobial peptides; FVIII: Tissue factor VIII; VWF: Von Willebrand factor; PAI-1: Plasminogen activator inhibitor-1; TLR: Toll-like receptor.

by SARS-CoV-2. The entry of CD4+ T cells is essential to immunity and chronic enteritis in the intestinal mucosa. It is known that C-C chemical receptor type 9 (CCR9) is an important chemical receptor for the introduction of CD4+T cells into small gut cells . Additionally, treatment with broad-spectrum antibiotics is a major risk factor for Clostridium difficile infection, which is considered the primary reason for nosocomial diarrhea [95] . It is unclear whether the above-mentioned factors including, the use of antibiotics or antiviral agents and increased gut inflammation along with a decrease in mammalian target of rapamycin (mTOR) activity, and antimicrobial peptides, are partly responsible alone or in combination for causing diarrhea in patients infected with COVID-19 via alterations in the gut flora[96]. Proton pump inhibitors (PPIs) are mainly used as a therapy for patients with peptic ulcers and gastroesophageal reflux disease. By blocking the proton pump, PPIs decrease gastric acid released into the stomach. Although the decrease in stomach acid can be beneficial in patients with stomach diseases, it can make the gut more susceptible to COVID-19 infection[97-99]. SARS-CoV S protein was suggested to fuse with patients' cells in neutral pH conditions. Additionally, Darnell et al[100] also established that highly acidic pH (1-3) and alkaline pH (12-14) may lead to inactivation of SARS-CoV, while, in the case of neutral pH, the virus remains stable[101]. Zhou et al [102] reported that, under the conditions of pH 1.0 and 2.0, SARS-CoV-2 was inactivated and unable to infect cells which was related to the pH in an empty stomach by creating viruses pseudotyped with SARS-CoV-2 S protein. In addition, the study by Ramachandran et al[103] found that prehospitalization PPI-exposed patients had worse clinical outcomes, involving mortality of COVID-19 patients, irrespective of the existence of cardiovascular diseases. A possible explanation for this is that secretions in the stomach are in the pH range 1.0 to 3.5, while the pH in the small and large bowels ranges from 7.5 to 8.0. SARS-CoV-2 can cause gastric acid to inactivate most virus particles. If a person has a long period of acid suppression with PPIs, the pH in the stomach decreases. SARS-CoV-2 can also have a higher rate of entry in the gut, which leads to viral infection.

In general, the existence of comorbidities is associated with dramatically low outcomes in COVID-19 patients. This may cause consequences for the management of previous gastrointestinal patients [104] . Patients that have inflammatory bowel disease (IBD) and have been treated with immunosuppressive drugs are more at risk for regular and serious infections and may be more at risk for SARS-CoV-2 infection [105] . It was reported in the IBD registry in Wuhan that none of 318 patients (204 patients with ulcerative colitis and 114 patients with Crohn's disease) had been infected with SARS-CoV-2 following precautions for COVID-19 control and prevention [106] . Thus, the use of biologics and immunosuppressants, diet therapy, deliberate postponement of elective and endoscopic surgery and provisions for personal safety are recommended [107] .

It is currently not recommended that IBD patients stop immunosuppressant drugs [11] . This is because there is a risk of disease reactivation in patients who discontinue their treatment, leading to severe inflammation, surgery, increased risk of hospitalization, and infection[108,109]. Non-hormonal anti-inflammatory drug use should be prohibited as the adverse effects of viral respiratory infections have been associated with triggering the reactivation of IBD [110] .

No evidence-based recommendations for immunosuppressed patients have been made by clinical parties. Table 2 shows the specific considerations for the treatment of IBD patients mainly based on specialist beliefs. These suggestions can be edited and updated as new evidence emerges [108, 110] . Overall, the same therapies can be used by patients with moderate to serious Crohn's disease or ulcerative colitis, regardless of COVID-19 infection [110] . IBD therapies can be restarted after 14 d for asymptomatic IBD patients with SARS-CoV-2 infection whose therapy has been stopped [110] .

It is noteworthy that IBD patients should discontinue immunosuppressant drugs until COVID-19 is resolved, and medications can be resumed after complete resolution of COVID-19 symptoms or after two negative polymerase chain reaction (PCR) tests [111] .

The new strain of coronavirus has increased the risk of severe pulmonary infection and extended hospitalization for IBD patients waiting for surgery, which is critical for IBD immunosuppressed patients. A recent report in Wuhan, China, demonstrated that 34 patients who underwent elective surgical procedures during the COVID-19 incubation period, developed COVID-19 pneumonia after surgery; 44.1% of patients were admitted to the ICU, and 20.5% of patients died [112] . Therefore, the majority of physicians have recommended postponing both elective and endoscopic surgery to protect patients and healthcare personnel and to minimize the usage of healthcare services and use personal protection equipment [113, 114] . Eventually, the ultimate goal is to ensure the safety of patients and health care workers.

A number of articles have disclosed that SARS-CoV-2 RNA can be found in patients' stool, suggesting that SARS-CoV-2 has the ability to be transmitted via the fecal-oral route [115] [116] [117] . Surprisingly, stool samples were positive in 17 (23.29%) patients but respiratory samples were negative and the period of positivity ranged from 1 to 12 d in stools. Xiao et al[49] demonstrated that infectious SARS-CoV-2 may be secreted from virus-infected gastrointestinal cells. Therefore, stool samples should be frequently tested using real-time-PCR and transmission-based precautions should be taken into consideration [119] .

Furthermore, the probability of SARS-CoV-2 fecal-oral transmission has highlighted the importance of adequate hand hygiene, especially in certain areas. Strict measures must be taken to deal with the stools of COVID-19 patients and the sewage from hospitals. Therefore, patients with preexisting gastrointestinal diseases will be more worried when they are infected with SARS-CoV-2 in addition to potential fecal microbiota transplant donors.

Microecological preparation: The intestinal flora generates various vitamins, bile acids, immune factors, and fatty acids via the decomposition of food and participates in immune system regulation[120]. If there is dysfunction or damage in the intestinal Other studies have stated that probiotics have the availability to manage diarrhea caused by rotavirus [121] . Also, lactic acid bacteria and Bifidobacteria can contribute to antiviral antibodies in the human body, accelerating virus removal. Therefore, probiotic treatments and/or antiviral drugs, and antibacterial drugs may enhance the symptoms of SARS-CoV-2 diarrhea. Regarding the diagnosis and treatment protocols of COVID-19 in China, the use of intestinal flora regulators is preferred to preserve the intestinal micro-environmental balance and avoid secondary bacterial infection[122].

As previously mentioned, ACE2 binds SARS-CoV-2 in cells. Therefore, to avoid SARS-CoV-2 infection the interaction between the receptor connection domain (RBD) of the virus and ACE2 could be blocked. A number of studies have shown that ACE2 inhibitors can regulate bowel metabolism, innate immunity, secretion of antibacterial peptides, and intestinal microbial homeostasis [122] . It was experimentally confirmed that the ACE2 pathway in epithelial cells of the small intestine trigger mTOR via nutrient stimulation and/or the tryptophan-nicoti-namide pathway, thus affecting the composition of intestinal flora, and decreasing GIT indications in mice [60] . Azathioprine is an immunosuppressive agent similar to chloroquine. A recent study evaluated azathioprine and found that it could be regarded as an ACE2 inhibitor [123] . Additionally, in vitro studies have shown that Vaccinia virus can be inhibited by azathioprine [124] . With regard to molecular immunity, azathioprine competitively binds to ACE2, using a single chain (ScFv) antibody fragment attached to ACE2 or SARS-CoV-2, via the RBD. Thus, the human recombinant ACE2 antibody Fc segment bound by the S protein works by inhibiting attachment of the virus to ACE2[55]. It has been documented that a combination of Chinese medicines (e.g., baicalin in the Chinese medicine Scutellaria baicalensis, scutellarin in Erigeron breviscapus, hesperetin in lime and orange peel, glycyrrhizin in liquorice, and nicotinamide in soybean) and ACE2 resulted in the prevention of SARS CoV-2 infection.

A number of COVID-19 patients have significant anorexia. To ensure effective therapy, the basic energy, absorption, enteral and peristalsis movement of the intestine, and normal function of GIT micro-organisms and mucosal immunity should be taken into account as well as the functioning of the GIT and patients' nutrition [94] . Nutritional risk assessment should be performed in patients with serious COVID-19 and gastrointestinal symptoms [125] . Once the risk of enteral nutrition has been eliminated, enteral nutrition should immediately be restored. If the patient has a gastrointestinal disorder and cannot withstand enteral nutrition, parenteral nutrition should be supplemented with a sufficient supply of energy. Patients in poor condition can be given digestive enzymes [125] . A nasogastric tube can be used for enteral feeding in patients who have undergone mechanical ventilation and are unable to take food orally. A nasal jejunal tube can be inserted when patients are at high risk of reflux aspiration or cannot handle nasogastric tube feeding. Generally, the patient gastrointestinal tolerability should be estimated appropriately and the enteral nutrition program correspondingly adjusted.

Hepatic injury is a frequent adverse event in both SARS-CoV and Middle East respiratory coronavirus-infected patients and is associated with the severity of disease [126] . A substantial systematic analysis of 11 studies assessing the liver laboratory parameters of 2541 patients with COVID-19 showed increased AST and/or ALT (25%), lactate dehydrogenase (20%), bilirubin (3%) and normal alkaline phosphatase (ALP) [127] . This may indicate minimal direct liver damage caused by ACE2 overexpression in cholangiocytes. A major published study of 5700 patients found that AST and ALT were increased in COVID-19 patients by 58.4% and 39.0%, respectively[128]. Cai et al [129] showed that in 41% of patients, gamma-glutamyl transferase (GGT) was increased more than 3 × ULN, while, another research study demonstrated that GGT was raised in severe cases, but without an elevation in ALP [126] .

Data from a preprint meta-analysis involving 20 retrospective studies and 3428 COVID-19 patients showed that increased levels of COVID-19 were related to significant increases in the levels of ALT, AST, and bilirubin [130] . Recently, a plethora of studies reported increased serum ALT, AST, and GGT levels in severe compared with mild or non-severe COVID-19 patients [39, 131] . A recent meta-analysis associated high marker admission levels with patient mortality [132] . Other studies have shown that the increase in these parameters resulted in a worse pulmonary computed tomography (CT) score [133] , increased numbers of ICU patients[12] and longer hospital stays [134] . In patients who died due to COVID-19, the incidence of elevated liver parameters ranged from 58.06% to 78% [32, 135] .

According to a study conducted by Lei et al [132] , AST was the first indicator to be considered high when patients were admitted to hospital and was correlated with the highest COVID-19 death rates. A recent study carried out by Guan et al [39] , around 1100 Chinese patients reported elevated levels of serum AST and ALT of 18% and 26% in non-severe COVID-19 patients, respectively, compared with 56% and 28% in severe COVID-19 patients. Previous findings revealed the crucial role of immune-mediated systemic inflammation in liver dysfunction in patients with serious COVID-19[9]. Recently, Gordon et al [136] proposed that mitochondrial proteins may interact directly July 28, 2021

Volume 27 Issue 28 with the virus, providing a cause for the high level of AST in the liver profile [136] . Wang et al [137] also identified anomalies in liver enzymes, higher radiologic scores as well as a partial pressure differential between alveolar arterial oxygen, higher GGT, disease intensity, higher ferritin, lower CD4+ T and B cells and lower albumin. It is considered that total bilirubin, AST/ALT, and ALT/ALP ratios have helped to predict survival in cirrhotic COVID-19 patients [138] . Serum albumin levels were also markedly lower in patients who died of COVID-19[32]. The adverse path of COVID-19 patients has been shown to include elevated serum levels of IL-6, ferritin, procalcitonin, and C-reactive protein. In addition to reduced albumin content and platelet count, the parallel increase in the level of ferritin, ALT and IL-6 indicates a greater role for liver participation in COVID-19 [32, 134] . The CT imaging score for pulmonary lesions is known as a hepatic injury indicator. Therefore, patients must undergo careful monitoring of liver function in order to identify any liver insults at an early stage [133] . The incidence of hepatic abnormalities in COVID-19 patients are depicted in Table 3 . Morphological findings regarding the interpretation and description of liver parenchymal changes accompanying COVID-19 are rare, and most are seen at autopsy. It is noteworthy that the first autopsy liver specimen examinations carried out by Xu et al [139] showed moderate microvesicular steatosis and both portal activity and mild lobular activity. SARS-CoV-2 infection or drug-related hepatic damage may result in this liver insult. These results matched with those of Liu et al [140] . Preliminary research, consisting of 49 patients with COVID-19, showed that the portal intrahepatic system was affected with acute (thrombotic and luminal ectasia) or chronic (fibrous thickening of the vascular wall) features and the intrahepatic blood vessels were abnormally configured. These findings indicated that the major trigger in the pathogenesis of COVID-19 hepatitis is considered endothelial damage or coagulation dysfunction [141] . Additionally, in patients with critical COVID-19 there were no signs of damage to bile ducts or histological changes in liver failure [140] . Several studies failed to identify viral inclusion bodies in liver tissue [139, 142] . Furthermore, the study by Li and Xiao[143] demonstrated that cirrhosis and regeneration signs with macrovesicular steatosis and accumulation in hepatocytes, along with atypical lymphocytic infiltration in the portal tract, may occur due to COVID-19. In the portal triad and centrilobular zones, sinusoidal expansion dilatation in zone 3, mild lymphocytic infiltrations and patchy liver necrosis were also revealed.

Moreover, the study by Ramachandran et al [144] showed that in hospitalized COVID-19 patients, elevated aminotransferases were associated with higher mechanical oxygen concentrations but did not achieve statistical significance after inflammatory marker measurement. In addition, patients with elevated aminotransferases did not have higher rates of mortality or prolonged length of stay as shown in Table 4 .

In China, some patients recovering from extreme COVID-19 were confirmed to have experienced special manifestations including a darkened face and pigmentation during treatment. The key causes of a darkened face and pigmentation were multiple organ injury, in particular liver injury [145, 146] . Abnormal hepatic function can easily lead to pigmentation via the following three pathways: (1) Liver dysfunction can prevent estrogen from being inactivated [147] . The rise in estrogen decreases thiamine inhibition of tyrosinase in vivo, thus increasing the transformation of tyrosine into melanin [148] ; (2) Abnormal liver function can cause hypofunction of adrenocortical hormones. The liver does not metabolize melanocytic stimulatory hormone produced by the anterior pituitary gland, which causes greater melanin secretion [149] ; and (3) Liver damage can cause bleaching of the face due to iron in the blood that provides the facial skin [150, 151] (Figure 4 ).

Direct damage: It is established that SARS-CoV-2 enters the host cells via its binding to ACE2 on the surface of the host cell by the S protein [152, 153] . However, the expression of ACE2 levels in liver tissue was estimated to be approximately 0.31% and its expression in bile duct cells was 20 times higher than that in hepatocytes on the basis of single cell sequencing and animal model analysis [154] . Furthermore, elevated levels of γ-glutamyl transferase and alkaline phosphatase were observed in COVID-19 patients [155] , and inconsistent with biliary epithelial cells injury, approximately 10% of COVID-19 patients have high levels of total bilirubin. Thus, suggesting that SARS-CoV-2 can bind to cholangiocytes expressing ACE2, resulting in their injury ( Figure 5 ).

Antibody-dependent enhancement of infection (ADE) may arise in patients with SARS [156] . ADE indicates that the interplay between the virus-based antibody and the CR and/or FC receptor complements increases the ability of the virus to reach macrophages, granulocytes, and monocytes ( Figure 5) . The virus frequently replicates in the aforementioned cells, leading to an increase in virus production and worsening of infection. Previous findings have indicated that SARS-CoV antibodies activate ADE, triggering SARS-CoV in immune cells that do not have ACE2 expression or harm the immune system [157] . Whether ADE can help SARS-CoV-2 infect immune cells through a non-ACE2-dependent pathway and participate in SARS-CoV-2 hepatic injury is an issue of concern.

Systemic inflammatory response syndrome and cytokine storms: Research has revealed that the inflammatory cytokines, including endotoxin ILs, and TNF-α in SARS patients who have liver function impairment have significantly higher levels than patients with normal liver function. Therefore, systemic inflammatory response syndrome Not only does such a vicious cycle lead to lung injury but may also progress to multiple organ damage. These results suggest that cytokine inflammatory storms may be one of the essential routes of liver injury ( Figure 5 ).

Ischemia and hypoxia reperfusion injury: COVID-19 patients have various degrees of hypoxia, as more than 40% of cases required oxygen supplementation [30] . Complications such as aspiration and multiple organ failure can cause hypoxia, ischemia and subsequent shock. The suppression of cell survival signal transduction and hepatocyte death may be caused by ischemia and hypoxia, ATP depletion in hepatocytes, lipid accumulation, and glycogen consumption ( Figure 5) . Furthermore, the respiratory distress syndrome can cause oxidative stress that increases the production of reactive oxygen species (ROS). The ROS and lipid peroxidation products can induce redox-July 28, 2021 Volume 27 Issue 28 sensitive transcription factors and then release various pro-inflammatory factors leading to liver damage. These changes can exaggerate the ischemia of hepatocytes, influence the excretion of toxic metabolites and eventually stimulate liver injury. Hypoxia is also one of the main causes of liver injury in patients with serious COVID-19 [161] .

Drug hepatotoxicity: In China, the occurrence of drug-induced hepatic damage including, traditional Chinese patent medicines [162, 163] , antitumor drugs, antibiotics, antimalarial drugs, and anti-tuberculosis drugs [164, 165] , is second only to fatty liver disease and viral hepatitis (alcoholic and nonalcoholic). Several COVID-19 patients have a fever and consequently, use antipyretic and analgesic drugs. Therefore, a drug overdose can cause hepatic damage.

Recently, this was observed with abidol, lopinavir, ritonavir and other antiviral medications used to control COVID-19. A recent study published in JCI[166] demonstrated that CAP3A4 plays a critical role of the side-effect and metabolic pathways of ritonavir which can generate electrophilic material, radical free oxygen that can be covalently linked with liver cells leading to lipid membrane peroxidation, membrane integrity disruption of the Ca2+-ATPase membrane, interruption of the internal and external Ca2+ homeostasis of the cells, and finally leading to death. Furthermore, an overdose of the combination of lopinavir and ritonavir can stimulate the hepatic endoplasmic reticulum stress cascade, induce inflammatory reactions, trigger hepatocyte apoptosis through the caspase mechanism, suppress hepatocyte growth, and aggravate liver damage by the production of oxidative stress [167, 168] . Some scientists have assumed that SARS-CoV-2 replication can be effectively inhibited by human immunodeficiency virus (HIV) protease inhibitors; although Shen et al stated that the risk of liver damage is increased in patients receiving hormones and HIV protease inhibitors [169] . The incidence of liver damage due to different medicines varies. However, the prevalence of liver damage due to more drug types is increasing. The diagnosis of hepatic damage due to medication includes a combination of medical history and appropriate testing to rule out other liver disorders and to estimate the relationship between hepatic injury and suspected medications by causality.

Due to the global spread of chronic liver disorders, correlations among patients presenting with hepatic illness and COVID-19 need to be examined. A preliminary analysis showed that 2%-11% of patients had hepatic disease and COVID-19 [170] . In a study of 1099 COVID-19 patients, hepatitis B infection occurred in 23 (2.1%) patients. Serious cases of hepatitis B infection were more likely (2.4% vs 0.6%) than milder cases [39] . SARS patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection were more vulnerable to serious hepatitis, likely because viral replication was increased during SARS-CoV infection [171] . Older patients with COVID-19 and have other conditions such as diabetes, cardiovascular disease, hypertension, and nonalcoholic fatty liver disease, are more susceptible to liver injury.

Moreover, patients with liver cirrhosis may be more susceptible to infection due to their systemic disease [172] , thus, preventing COVID-19 is extremely important. None of 111 patients with COVID-19 in Wuhan had decompensated cirrhosis due to preventive measures. In contrast to this, 17% of 101 patients with COVID-19 developed decompensated cirrhosis at other hospitals where preventive measures were not implemented [173] . Viral transmission could occur during liver transplantation from donor to recipient, as previously described in SARS infection [174] . Recently, Michaels and colleagues showed potential transplantation risks in COVID-19 recipients [175] . The Italian Transplant Authority is carrying out nasopharyngeal swabs to diagnose COVID-19 before donation, with the subsequent exclusion of positive donors [176] .

The worldwide spread of COVID-19 raises additional challenges for organ transplants. Transplant recipients with preoperative decompensated organs and chronic illness tend to contract respiratory viruses. Liver transplant patients, who are exposed to more people, during their wait for transplantation, have an increased risk of cross-infection with COVID-19. Qin et al [177] confirmed COVID-19 hepatocellular carcinoma in a patient following liver transplantation. On the 11 th day after hepatic transplantation, the patient was diagnosed with COVID-19 following a positive PCR-test, with multiple ground-glass opacities in the left lobes. Long-term immune treatment in transplantation recipients prevents allograft rejection but significantly reduces the ability to protect them against COVID-19 due to their compromised immune system. A systematic analysis of 15 studies involving 223 patients with confirmed COVID-19 showed that simultaneous diarrhea was more likely to be present in patients who had undergone liver transplantation. The higher mortality rates in elderly patients with dyspnea and diabetes were approximately 23% in COVID-19 patients [178] . However, the latest data still do not confirm susceptibility to COVID-19 in liver transplant patients. A number of cases in Italy have indicated that children receiving liver transplants were not at elevated risk of serious lung disease relative to the general population despite being immunocompromised [179] . Similarly, three COVID-19-related deaths observed by D'Antiga [179] at an Italian transplant center were long-term patients on a minimal immunosuppression regimen, rather than recently transplanted patients with complete immunosuppression. Furthermore, a large global observational study by Webb et al [180] showed that the risk of death in COVID-19 patients does not substantially increase following liver transplantation.

COVID-19 causes mainly transient and indirect liver injuries, which can be caused by hypoxia, systemic inflammatory reactions, and medication. Thus, hepatic damage should be treated by elimination of the basic etiology in the COVID-19 patients. Correction of hypoxia by oxygen supplementation or mechanical ventilation, renal replacement treatment for cytokine storm, and restoration of intravascular effectiveness can enhance liver injuries in the event of septic shock [181] . Also early identification and reduction in the dosage of drugs inducing hepatic damage is crucial. Hepatoprotective anti-inflammatory medicines including L-ornithine-L-aspartate can be used in extreme cases as an adjuvant treatment [182] . It is worth noting that therapeutic drugs may be hepatotoxic, especially in chronic liver disease (CLD) patients. Furthermore, patients treated with immunosuppressive agents should be closely monitored due to drug interactions. Recommendations for the management of CLD, AIH, and immunosuppressed patients during a pandemic are summarized in Tables 5, 6 and 7 [183, 184] .

Although millions of people have remained at their houses to decrease the transmi- ssion of SARS-CoV-2, the risk of COVID-19 amongst health workers is high.

For example, the Chinese National Health Commission determined that approximately 3300 health workers were infected in early March [185] . It is well-known that endoscopic staff are at high risk of airborne droplet infection, conjunctiva contact and surface contact contamination [182, 186] . Airway suction and other cough-induced procedures result in an increased risk of SARS-CoV-2 transmission [182] . It must be noted that the possible risk of exposure to feces removal is not confined to upper endoscopy[35]. A prospective study conducted by Johnston et al [187] , revealed the quantification of unrecognized bacteria to endoscopists exposed to biological samples leading to infection transmission. In this investigation, 227 endoscopic face shields were examined for colony-forming units (CFUs), and 1-15 CFU, 91/227 (40%); 16-30 CFU, 6/227 (2.6%); 30 or more CFU, 6/227 (2.6%) significantly increased after endoscopy. Similarly, in 1999, a research study carried out by Mohandas and Gopalakrishnan[188] in a tertiary care hospital in India of 786 endoscopies (149 lower and 162 therapeutic endoscopies) concluded that the splash rate to the skin of the forearms, feet, and face was 9.5%, while the splash rate to the eyes was 4.1%.

The duodenoscope is the most complex medical equipment that undergoes disinfection after patient use [189] . Virus risk factors include non-compatibility with disinfection guidelines, the promotion of biofilm deposition because of its complicated nature, surface defects and infected automated endoscopes [190, 191] . It is considered that endogenous infections due to the gut flora of patients are the most common infections after endoscopy [192] . Exogenous infections such as Escherichia coli (71%), Klebsiella (14%), and Enterobacter (5%) can occur due to contaminated scopes and may be avoided by thorough cleaning [192, 193] . Currently, Pseudomonas aeruginosa is the most common organism isolated from contaminated endoscopes [194] . Other microorganisms include, Mycobacteria, Helicobacter pylori, Clostridium difficile, HBV and HCV [195] . Recently, studies on duodenoscopy-associated infections including multidrugresistant organisms, particularly carbapenem-resistant Enterobacteriaceae, have surfaced [196] . Numerous infections occurred despite sufficient disinfection, indicating that professional and government bodies should provide additional recommendations for duodenoscope processing [197, 198] . To date, The Food and Drug Administration and Centers for Disease Control and Prevention have recommended comprehensive cleaning followed by high-level disinfection for reprocessing of flexible GI endoscopes [199] [200] [201] .

In COVID-19 patients single-use duodeno-scopes may be important. However, they are not accessible worldwide and have cost-related constraints [202] . Several societies have advocated the use of room negative pressure, particularly for COVID-19 patients, or if endoscopy is urgently needed [203] . Intraprocedural changes such as minimal verbal communication, avoiding procedures in patients with inadequate bowel preparation, and avoiding spillage of GI contents via the biopsy channel should be introduced [204] . A previous study reported the use of a "double gauze technique"; one for the endoscopists and the other for technicians in a controlled fashion to prevent the "whip" effect of accessories and spillage of GIT secretions [204] Institutional requirements for minimum staff involved in the procedure have been developed [205] . Thus, the risk of exposure among endoscopy personnel is diminished. Endoscopy techniques performed with moderate sedation without the need for anesthetic agents (endoscopy driven sedation) can also reduce the risk of transmission. However, in the case of procedures requiring general anesthesia, policymakers recently recommended the use of endotracheal intubation to diminish the risk of aerosolization due to suspected or confirmed COVID-19 [206] . Other methods to avoid splashes include the use of regular precautions such as full-sleeve gowns and suitable footwear [187] .

Although there is a theoretical risk of fecal-oral transmission of COVID-19, the actual risk of transmission is extremely low. Despite this risk, endoscopy units have been functioning and reopening with no significant outbreaks noted.

COVID-19 can lead to lead to acute respiratory infection, and a high rate of morbidity and mortality. The main signs of COVID-19 are respiratory system reactions, and gastro-intestinal symptoms are also very common. COVID-19 patients with GIT symptoms are more probably associated with severe complications such as ARDS and liver damage, with a poor prognosis. Hence, during diagnosis and treatment of the disease, GIT symptoms should be taken into consideration as well as virus transmission via the fecal-oral route. In addition, it is advisable to take care of patients with chronic liver disease and they should be treated with medications that are able to prevent inflammatory responses and protect liver functions during COVID-19. Furthermore, the harmful effects of some drugs on the gut and liver during hospitalization must be identified and evaluated frequently. Further studies on the intrinsic relationship between COVID-19, hepatology and gastroenterology are urgently required. 

COVID-19 in the New York City Area

COVID-19: Abnormal liver function tests

Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies

Liver Biochemistries in Hospitalized Patients With COVID-19

Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China

Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study

Clinical Features of COVID-19-Related Liver Functional Abnormality

Clinical characteristics of 82 death cases with COVID-19

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Gross examination report of a COVID-19 death autopsy

Liver and COVID 19 Infection: A Very Preliminary Lesson Learnt from Histological Post-mortem Findings in 48 patients

Hepatic involvement in COVID-19 patients: Pathology, pathogenesis, and clinical implications

Increased Serum Aminotransferase Activity and Clinical Outcomes in Coronavirus Disease

Doctor blackened after successful rescue? Expert: It could be multiple organ damage

Skin darkens in patients with COVID-19: don't ignore the medical reasons

Cholestasis-induced bile acid elevates estrogen level via farnesoid X receptor-mediated suppression of the estrogen sulfotransferase SULT1E1

Effects of estrogen and estrogen receptor in normal human melanocytes

Liver abnormalities and endocrine diseases

Liver iron sensing and body iron homeostasis

Liver iron transport

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After

Available from: bioRxiv

Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city

Antibody-dependent enhancement of virus infection and disease

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile

Hepatic complications of COVID-19 and its treatment

A comprehensive review and perspectives on pharmacology and toxicology of saikosaponins

Saikosaponins induced hepatotoxicity in mice via lipid metabolism dysregulation and oxidative stress: a proteomic study

Classification, hepatotoxic mechanisms, and targets of the risk ingredients in traditional Chinese medicine-induced liver injury

Cell death in drug-induced liver injury

Pregnane X receptor activation potentiates ritonavir hepatotoxicity

HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes

Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways

Incidence and Etiology of Drug-Induced Liver Injury in Mainland China

Liver injury in COVID-19: management and challenges

Study of the relationship SARS and hepatitis virus B

Liver -guardian, modifier and target of sepsis

Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis

Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening

Coronavirus disease 2019: Implications of emerging infections for transplantation

Coronavirus disease 2019 and transplantation: A view from the inside

Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient

Clinical Presentation, Treatment, and Mortality Rate in Liver Transplant Recipients With Coronavirus Disease 2019: A Systematic Review and Quantitative Analysis

The Facts During the Third Epidemic

Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study

Etiology and management of liver injury in patients with COVID-19

Factors involved in the aerosol transmission of infection and control of ventilation in healthcare premises

Synthesis of Liver Associations Recommendations for Hepatology and Liver Transplant Care During the COVID-19 Pandemic

Chronic Liver Disease and COVID-19: Alcohol Use Disorder/Alcohol-Associated Liver Disease, Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Autoimmune Liver Disease, and Compensated Cirrhosis

COVID-19: protecting health-care workers

A novel coronavirus outbreak of global health concern

Risk of bacterial exposure to the endoscopist's face during endoscopy

Mucocutaneous exposure to body fluids during digestive endoscopy: the need for universal precautions

Preventable tragedies: superbugs and how ineffective monitoring of medical device safety fails patients. Rockville: Agency for Healthcare Research and Quality

Lappin-Scott HM. Microbial biofilms

Is biofilm accumulation on endoscope tubing a contributor to the failure of cleaning and decontamination?

Antibiotics, biliary sepsis, and bile duct stones

Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis

Current issues in endoscope reprocessing and infection control during gastrointestinal endoscopy

Transmission of infection by flexible gastrointestinal endoscopy and bronchoscopy

Outbreaks of carbapenem-resistant Enterobacteriaceae infections associated with duodenoscopes: What can we do to prevent infections?

Multisociety guideline on reprocessing flexible GI endoscopes: 2016 update

Supplemental Measures to Enhance Duodenoscope Reprocessing: FDA Safety Communication

Reprocessing medical devices in health care settings: validation methods and labeling guidance for industry and Food and Drug Administration staf

Guideline for disinfection and sterilization in healthcare facilities

Brief Summary of the Gastroenterology and Urology Panel of the Medical Devices Advisory Committee Meeting

Clinical Evaluation of a Single-Use Duodenoscope for Endoscopic Retrograde Cholangiopancreatography

Dinis-Ribeiro M. ESGE and ESGENA Position Statement on gastrointestinal endoscopy and the COVID-19 pandemic

Approach to Endoscopic Procedures: A Routine Protocol from a Quaternary University Referral Center Exclusively for Coronavirus Disease

Anesthesia-administered sedation for endoscopic retrograde cholangiopancreatography: monitored anesthesia care or general endotracheal anesthesia?

Chinese Society of Anesthesiology; Chinese Association of Anesthesiologists. Perioperative Management of Patients Infected with the Novel Coronavirus: Recommendation from the Joint Task Force of the Chinese Society of Anesthesiology and the Chinese Association of Anesthesiologists

First 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore

Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis

Virological assessment of hospitalized patients with COVID-2019

IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study

COVID-19 National Incident Room Surveillance Team. COVID-19

Korea Centers for Disease Control and Prevention. Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea

Sex differences in the frequency of gastrointestinal symptoms and olfactory or taste disorders in 1942 nonhospitalized patients with coronavirus disease 2019 (COVID-19)

Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Chongqing municipality, China: a retrospective, descriptive, multiple-center study

Epidemiological and clinical characteristics of COVID-19 in Shenzhen, the largest migrant city of China

Manifestations of digestive system in hospitalized patients with novel coronavirus pneumonia in Wuhan, China: a single-center, descriptive study

Effect of SARS-CoV-2 infection upon male gonadal function: A single center-based study

A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients

The cross-sectional study of hospitalized coronavirus disease 2019 patients in Xiangyang, Hubei province

Clinical and Laboratory Profiles of 75 Hospitalized Patients with Novel Coronavirus Disease

The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Association of Digestive Symptoms and Hospitalization in Patients With SARS-CoV-2 Infection

Prevalence and Characteristics of Gastrointestinal Symptoms in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States: A Multicenter Cohort Study

SARS-CoV-2 infection in 86 healthcare workers in two Dutch hospitals in March 2020: a cross-sectional study with short-term follow-up

Clinical characteristics of moderate COVID-19 patients aggravation in Wuhan Stadium Cabin Hospital: A 571 cases of retrospective cohort study

Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan

Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region

Acute kidney injury at early stage as a negative prognostic indicator of patients with COVID-19: a hospital-based retrospective analysis

COVID-19 in a designated infectious diseases hospital outside Hubei Province, China